Abstract YO23
Case summary
Soft tissue Giant cell tumor presented as Nasopharyngeal mass : A case Report
ABSTRACT:
Background:
Primary soft tissue giant cell tumors are exceedingly rare. These often present in the elderly and are mostly noted on the extremities. Morphologically, these tumors resemble their osseous counterparts but sequencing studies have suggested that these two may be genetically distinct. Surgical extirpation remains standard of treatment; but for those with unresectable disease treatment options are less clear. For these patients, the use of bisphosphonates and RANK-L directed biologic therapy have been reported in the literature.
Case presentation:
A 30 year old male consulted at our medical oncology clinic with the chief complaint of diplopia. Magnetic resonance imaging (MRI) of the head revealed an enhancing soft tissue mass at the nasopharyngeal wall measuring 5.8x5.5x5.1cm extending anteriorly at the posterior margin of the nasal cavity, both parasellar regions, leptomeningeal region of the medial aspect of both middle cranial fossa, and infiltrating into the clivus. No distant metastasis was seen. Punch biopsy of this nasopharyngeal mass favored a giant cell tumor. Immunohistochemical staining was done with the following results: Cytokeratin negative, CD68 positive, and Vimentin positive, all consistent with giant cell tumor. Due to its location, the tumor was regarded to be unresectable. Zoledronic acid was given once every 28 days for 3 months. Cranial CT scan done after three months of treatment revealed an enhancing nasopharyngeal mass measuring 6.0x5.0x4.0cm with intracranial extension. At this time despite demonstrating stable disease, the patient was noted to have worsening of symptoms and was then shifted to Denosumab.
Conclusion:
We have reported a case of a nasopharyngeal giant cell tumor, which is an uncommon presentation of a rare soft tissue tumor. While surgery is the preferred treatment for this disease, the location of this tumor precluded resection. This has prompted the decision to employ systemic treatment with Zoledronic acid and subsequently Denosumab for this patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract